Lipanthyl

Fenofibrate, the active ingredient in Lipanthyl, is a fibrate presented as an oral tablet for oral use. It is used to lower elevated triglyceride and cholesterol levels in patients with hypertriglyceridaemia, mixed dyslipidaemia, or as adjunct therapy for primary hypercholesterolaemia.

GNH USA supplies Lipanthyl as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lipanthyl (fenofibrate) acts on lipid metabolism disorders and is indicated for the following conditions:

- Hypertriglyceridaemia: reduces triglyceride concentrations and lowers risk of pancreatitis. - Mixed dyslipidaemia: decreases triglycerides and modestly raises HDL‑cholesterol while lowering LDL‑cholesterol. - Primary hypercholesterolaemia (adjunct therapy): enhances the lipid‑lowering effect of statins when used together.

Fenofibrate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia. - Headache: mild to moderate intensity. - Elevated liver enzymes: transient increase in ALT or AST.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown that may cause renal failure. - Severe liver injury: hepatitis or hepatic failure. - Allergic reactions: rash, pruritus, angioedema or rare Stevens‑Johnson syndrome.

When prescribing fenofibrate, clinicians should consider several safety measures.

- Monitor liver function: check ALT/AST before and during therapy. - Assess renal function: adjust use in patients with impaired kidneys. - Review concomitant statin therapy: increased risk of myopathy. - Avoid use in pregnancy: contraindicated due to fetal risk. - Counsel on muscle symptoms: advise patients to report unexplained muscle pain or weakness. - Store at room temperature: keep in original packaging, protect from moisture and light.

Fenofibrate interacts with several medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid): - Gemfibrozil: combined use markedly increases risk of myopathy. - High‑dose statins (e.g., rosuvastatin >20 mg): may precipitate rhabdomyolysis. - Cyclosporine: elevates fenofibrate plasma levels, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Warfarin: fenofibrate can enhance anticoagulant effect, requiring INR monitoring. - Oral hypoglycemics (e.g., sulfonylureas): may increase hypoglycemia risk. - Thyroid hormone replacement: fenofibrate may alter thyroid hormone levels.